SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 643.94+2.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI8/30/2021 11:33:11 AM
  Read Replies (1) of 3557
 
PFE’s Abrocitinib bests Dupixent in_head-to-head_AD—no_futher_details_yet:

businesswire.com

This is the only phase-3 trial of Abrocitinib that used market-leading Dupixent as a comparator. The FDA review of PFE’s NDA for Abrocitinib in AD in on hold while the FDA completes its safety review of the entire JAK class.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News